Deadline Alert: Beta Bionics, Inc. Investors Have Until November 3, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds Investors

Beta Bionics, Inc. investors have until November 3, 2026 to request appointment as lead plaintiff in a securities fraud class action lawsuit. The complaint alleges the company failed to disclose material adverse facts regarding FDA Form 483 findings, including over 18,000 complaints and life-threatening hypoglycemic events that were not properly investigated or reported. The stock fell 37% on January 9, 2026 following disappointing preliminary fourth quarter 2025 financial results.